Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) has received an average rating of “Hold” from the six analysts that are covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating and four have given a buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $21.00.

CRBP has been the topic of a number of research reports. Cantor Fitzgerald set a $24.00 target price on Corbus Pharmaceuticals Holdings and gave the stock a “buy” rating in a research report on Tuesday, June 13th. Noble Financial reaffirmed a “buy” rating on shares of Corbus Pharmaceuticals Holdings in a research report on Friday, June 16th. BidaskClub raised Corbus Pharmaceuticals Holdings from a “sell” rating to a “hold” rating in a research report on Saturday, July 8th. Finally, ValuEngine lowered Corbus Pharmaceuticals Holdings from a “hold” rating to a “sell” rating in a research report on Wednesday.

Corbus Pharmaceuticals Holdings (CRBP) traded up 2.29% during midday trading on Wednesday, hitting $6.70. The company had a trading volume of 417,633 shares. The firm’s market capitalization is $336.47 million. Corbus Pharmaceuticals Holdings has a 1-year low of $4.65 and a 1-year high of $10.78. The company has a 50 day moving average price of $6.40 and a 200 day moving average price of $6.98.

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last issued its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.04. Corbus Pharmaceuticals Holdings had a negative return on equity of 107.10% and a negative net margin of 1,001.77%. The company had revenue of $0.35 million for the quarter, compared to analyst estimates of $0.50 million. Equities research analysts forecast that Corbus Pharmaceuticals Holdings will post ($0.66) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://www.thecerbatgem.com/2017/09/14/corbus-pharmaceuticals-holdings-inc-crbp-given-consensus-rating-of-hold-by-brokerages.html.

Several large investors have recently modified their holdings of the company. Bank of New York Mellon Corp grew its holdings in Corbus Pharmaceuticals Holdings by 7.7% during the first quarter. Bank of New York Mellon Corp now owns 21,102 shares of the biopharmaceutical company’s stock worth $174,000 after buying an additional 1,511 shares in the last quarter. Raymond James Financial Services Advisors Inc. grew its holdings in Corbus Pharmaceuticals Holdings by 5.5% during the first quarter. Raymond James Financial Services Advisors Inc. now owns 403,886 shares of the biopharmaceutical company’s stock worth $3,332,000 after buying an additional 21,125 shares in the last quarter. Quantbot Technologies LP bought a new stake in Corbus Pharmaceuticals Holdings during the first quarter worth $114,000. SG Americas Securities LLC bought a new stake in Corbus Pharmaceuticals Holdings during the first quarter worth $148,000. Finally, IPG Investment Advisors LLC bought a new stake in Corbus Pharmaceuticals Holdings during the first quarter worth $109,000. 31.78% of the stock is currently owned by institutional investors.

About Corbus Pharmaceuticals Holdings

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.

Receive News & Stock Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related stocks with our FREE daily email newsletter.